Novavax is a biotechnology company based in Gaithersburg, Maryland, focused on developing recombinant vaccines, including its COVID-19 vaccines Nuvaxovid and other candidates. The company employs 1,543 people and utilizes advanced nanoparticle technology and its Matrix-M adjuvant to enhance immune responses.
NVAX has been in the news recently: Novavax Inc. received FDA approval for its COVID-19 vaccine Nuvaxovid and secured a $175 million milestone payment from its partner, Sanofi SA. Meanwhile, U.S. stock futures and major indices, including the Nasdaq Composite, experienced declines in premarket trading on Monday.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
